This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Care Reform Is Healthy

NEW YORK ( TheStreet) -- President Obama is putting pressure on Congress to finalize health care reform legislation before the end of the year, and this is likely to make the health care and medical sectors even more compelling.

The sector has been attractive to investors because of several factors: The elderly population is growing; there has been an increase in diseases and cancer rates; and Americans generally want to live longer and healthier lives. In addition, health care companies have seen continuous year-over-year revenue growth.

The proposed reform is expected to further accentuate the sector's appeal by increasing accessibility to prescription drugs and turning tens of millions of previously uninsured people to into health care customers.

You'd think that those affiliated with the industry would be smiling from ear to ear, but they're not. Opponents of the legislation are against the idea of a government-run insurance program, and drug makers are upset over the billions of dollars in rebates they will have to fork over to the government over the next decade. Additionally, medical device providers are upset because they will be forced to pay a 2.5% tax to the government on all of their products.

At the end of the day though, there is hope for the sector, in particular drug makers and hospitals. Lobbyists for Big Pharma have managed to include an $80 billion rebate agreement in the reform, while also successfully winning a fight that would have required some of its largest players to pay back another $106 billion in additional rebates over 10 years.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
IHF $128.08 0.00%
IHI $117.07 0.00%
VHT $133.64 0.00%
AAPL $125.01 0.00%
FB $78.10 0.00%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs